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A Promising Proposition in Need of Validation*Benjamin D. Horne, PHD, MPH,yz Jeffrey L. Anderson, MDyzD iscoveries in human genetics have occurredrapidly over the last 15 years. The HumanGenome Project launched a new era of
biotechnology that empowered previously impos-
sible research, including genome-wide association
studies and whole-genome sequencing (1). Despite
early failures and limited advances in medical app-
lications of genetics over this same period, recent
rapid advances have kept alive the hope of geneti-
cally driven personalized medicine (2). Although
personalized care has not developed as dramatically
as was hoped in cardiovascular medicine, advances
have been made in understanding the inheritance of
cardiac risk factors (e.g., cholesterol, blood pressure,
and metabolic factors), identifying previously unrec-
ognized risk pathways (e.g., chromosome 9p21.3),
evaluating medication safety via pharmacogenetics
(e.g., warfarin, clopidogrel), and developing medica-
tions for reducing cardiovascular risk (e.g., PCSK9
inhibitors) (1). These innovations would not have
occurred without the ability to replicate an initial
genetic association, the development of hypothesis-
free designs such as genome-wide association
studies, and the collaborative work in international
consortia that sometimes evaluate dozens of popula-
tions (1).
Historically, genetic discoveries in adult cardio-
vascular medicine were rejected because of the
inability to validate an initial ﬁnding, in part due to*Editorials published in the Journal of the American College of Cardiology
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studies began with a positional candidate gene iden-
tiﬁed via linkage analysis or a biologically functional
candidate gene, and then were carried out in 1 or a few
populations (3). Although useful for monogenic dis-
eases, this approach represents a poor design for
evaluating genetic inﬂuences on common, complex
diseases such as coronary heart disease (CHD).
Haptoglobin (Hp) is a plasma protein produced in
the acute response to infection or inﬂammation. Hp
binds oxygenated free hemoglobin, protecting the
body from oxidative damage. An Hp genetic variant
(Hp2-2) produces a dysfunctional protein that is less
able to protect against oxidation than the products of
Hp1-1 and Hp2-1 variants. Evidence suggests that
Hp2-2 is associated with intermediate phenotypes
that lead to worse CHD outcomes. Studies of the as-
sociation of Hp2-2 with clinical CHD endpoints un-
fortunately have produced mixed results (4). Some
evidence suggests that Hp2-2 is associated with a
greater risk of myocardial infarction (MI) and coro-
nary artery disease overall, whereas other data sug-
gest that the Hp2-2 effect may be limited to patients
with elevated glycosylated hemoglobin (HbA1c), and
still other studies failed to ﬁnd an association (4–7).
Speciﬁcally, the proposed interaction between
Hp2-2 and HbA1c has produced mixed results. In 2013,
Cahill et al. (5) reported that Hp2-2 was associated
with CHD in 3 populations but only among subjects
with HbA1c $6.5%. The number of CHD events
(nonfatal MI or CHD death) was relatively low across
the 3 studies (93 CHD events total among Hp2-2
subjects) (5). In 2014, Pechlaner et al. (6) did not
replicate the ﬁnding in a fourth population, with re-
sults indicating a weak trend toward a protective ef-
fect of Hp2-2 in the context of HbA1c $6.5%; however,
only 8 total events were found in the Hp2-2 group,
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1801and CHD events accounted for fewer than one-half of
the composite endpoint (stroke was the other event)
(6). We also were unable to validate the Cahill et al.
(5) ﬁnding of an interaction of Hp2-2 and HbA1c for
CHD events in Intermountain Healthcare data, but
due to the challenges of reporting negative genetic
results (3), these data remain unpublished.SEE PAGE 1791In this issue of the Journal, an evaluation of a
new study population (29 CHD events in Hp2-2/
HbA1c $6.5% subjects) and a reanalysis of the ﬁrst
population (24 CHD events) are presented (7). Al-
though on the surface, this paper is another valida-
tion of the Hp/HbA1c interaction, it should be noted
that Cahill and colleagues have altered the ori-
ginal hypothesis (Figure 1): they examine whether
HbA1c $6.5% is associated with CHD outcomes in
subjects with the Hp2-2 genotype (instead of whether
Hp2-2 predicts events exclusively in people with
HbA1c $6.5%) (7). In both study populations, elevated
HbA1c (a known risk factor) was veriﬁed to be asso-
ciated with poor CHD outcomes overall and wasFIGURE 1 Comparison of Genetic Interaction Study Designs
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show a greater ability to stratify risk in Hp2-2 than
Hp1-1/2-1 subjects, a signiﬁcant statistical interac-
tion was not shown (7). In secondary analyses,
HbA1c $6.5% was especially strong for CHD risk pre-
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Importantly, the Cahill et al. (7) paper examines Hp
genotype data from a new perspective that may be
useful for precision medicine when using genetic
markers from across the genome. The study utilized a
genetic marker (Hp2-2) to identify a subpopulation
within which to evaluate a standard clinical risk
marker (HbA1c). This approach is a paradigm shift
from the traditional concept wherein a clinical sub-
population (e.g., those with HbA1c $6.5%) is studied
to determine whether a genetic risk marker (Hp2-2)
predicts events (5,6). If the gene or genes utilized
for this unusual approach are carefully tuned to
the clinical therapeutic area and the cost–beneﬁt
analysis is favorable, genetic testing could represent a genetic variant and clinical risk marker
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the likelihood of responding to treatment (e.g.,
identifying groups in which lowering of HbA1c is more
successful using current medications) or based on the
risk of CHD events (e.g., identifying high-risk groups
in which a more intensive patient care plan is justiﬁed
by a greater potential beneﬁt).
Although this risk stratiﬁcation approach is in-
triguing, it creates a plethora of new questions: Can
the trends reported be replicated and strengthened
(or refuted)? Is Hp the best gene to use for this clinical
application when many other genes could be consid-
ered? Should a genetic risk score of HbA1c-related
genes be used instead? Also, would it not be better to
use a genome-wide or genome-sequencing approach
to ﬁnd all important variants? The use of genetics as a
ﬁrst-line stratiﬁcation tool before or simultaneously
with evaluating standard risk markers could also
be applied elsewhere (e.g., cholesterol- or blood
pressure–lowering). By contrast, is it possible to
obtain equally excellent, but lower-cost, risk stratiﬁ-
cation using tools (8) that do not require genetic
information? The hurdles for this gene-based strati-
ﬁcation method are high.
Finally, this study of Hp genotypes highlights the
difference between scientiﬁc validity and clinical
usefulness (7). The drive to validate genetic variants
for prediction of CHD events (e.g., Hp or the chro-
mosome 9p21.3 CHD locus) continues to over-
shadow the limited demonstrated practical value of
clinical genetic testing (i.e., proven ability to guide
preventive therapy leading to improved outcomes).
In the case of warfarin pharmacogenetics, even theconsistent replication of genetic associations with
health outcomes has not yet translated into clinical
usefulness, in part due to the costs and timeliness of
genetic testing in the presence of marginal incre-
mental clinical beneﬁt. Considerable inﬂux of capital
investments into cardiovascular genetics has not yet
overcome the clinical usefulness issues. At present,
human genetics remains primarily a source of
knowledge regarding human biology and potential
drug targets (2).
In conclusion, the application of genetics for patient
risk stratiﬁcation is a relevant ongoing goal in adult
cardiovascular medicine. The potential use of genetic
information to better target diagnosis and treatment,
as evaluated by Cahill et al. (7), is timely in this era
characterized by an emphasis on efﬁcient medical
practice, but it will require substantial additional
methodological development. Although we agree with
Cahill et al. on the need for further replication of their
speciﬁc ﬁndings, we propose that hypothesis-free ge-
netic methods should be applied to identify all genetic
variants that may be useful for risk stratiﬁcation,
including methods that evaluate copy number vari-
ants. The clinical usefulness of genetic testing should
be particularly considered in research studies to
determine whether adding the complexity and ﬁnan-
cial costs of genetics to medical care is warranted.
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